Pfizer Inc. diskutieren
Pfizer Inc.
WKN: 852009 / Symbol: PFE / Name: Pfizer / Aktie / Pharmazeutika / Large Cap /
26,00 €
1,31 %
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $39.00 price target on the stock, up previously from $38.00.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at BMO Capital Markets from $44.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at Truist Financial Co. from $62.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $42.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at Truist Financial Co. from $42.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $36.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $36.00 price target on the stock, up previously from $33.00.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Pfizer Inc. (NYSE: PFE) was upgraded by analysts at Daiwa Capital Markets from a "neutral" rating to an "outperform" rating.
Ratings data for PFE provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Metlife Inc. diskutieren